News

Lynavoy (linerixibat) is now approved in the U.S. as an oral treatment for cholestatic pruritus, or intense itch due to problems in how the digestive…

Backed by millions in U.S. funding, scientists from Johns Hopkins Medicine in Baltimore will be leading a new international consortium working to find a cure…

A noninvasive MRI-based approach may help assess disease severity and predict the likelihood of serious complications in people with primary sclerosing cholangitis (PSC), a…

A global clinical trial testing Mirum Pharmaceuticals’ oral therapy maralixibat in people with itching, or pruritus, due to rare cholestatic conditions has finished…

Sagimet Biosciences said it expects a clinical trial testing a combination therapy in people with cirrhosis, or irreversible liver scarring, due to metabolic dysfunction-associated steatohepatitis…

A new artificial intelligence (AI)-based model that combines information from imaging scans and blood levels of a protein called matrix metalloproteinase-7 (MMP-7) may aid in…

A late-stage clinical trial assessing the safety and effectiveness of Mirum Pharmaceuticals’ brelovitug for adults with chronic hepatitis D has completed enrollment, and…

Hispanic people with primary biliary cholangitis (PBC) are significantly less likely to achieve complete lab-based remission — defined as a normalization of the liver damage…

Long-term exposure to particles produced from cooking grilled meat can trigger liver damage and cholestasis — slowing or stalling of the digestive fluid bile…

The first participant has been dosed in a large clinical trial testing TGM-312, a novel gene-silencing therapy designed to slow the progression of metabolic dysfunction-associated…